A meta-analysis of seven observational studies showed that insulin use was associated with a significant increased risk of HCC, compared to non-use (OR 2.61, 95% CI 1.46–4.65) and this oncogenic effect was confirmed regardless of study design and the concomitant effect of other antidiabetic drugs. Here, INS is linked to hepatocellular carcinoma.